Anika TherapeuticsANIK
Recorded

Anika Therapeutics 2026 Q2 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ2 2026Duration35 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, ladies and gentlemen, and welcome to Anika's second quarter earnings conference call. I would now like to turn the call over to Mr. Matt Hall, Executive Director of Corporate Development and Investor Relations.

Matt HallExecutive Director of Corporate Development and Investor Relations

Please proceed. Good morning, thank you for joining us for Anika's second quarter 2026 conference call and webcast.

Matt HallExecutive Director of Corporate Development and Investor Relations

I'm Matt Hall, Anika's Executive Director of Corporate Development and Investor Relations. Our earnings press release was issued earlier this morning and is available on our investor relations website located at www.anika.com, as are the supplementary PowerPoint slides that will be used for the discussion today. With me on the call are Steve Griffin, President and Chief Executive Officer, and Ian McLeod, Senior Vice President, Chief Accounting Officer, and Treasurer. They will present our second quarter 2026 financial results and business highlights. Please take a moment and open the slide presentation and refer to Slide two. Before we begin, please understand that certain statements made during today's call constitute forward-looking statements as defined in the Securities Exchange Act of 1934.

Matt HallExecutive Director of Corporate Development and Investor Relations

These statements are based on our current beliefs and expectations and are subject to certain risks and uncertainties. The company's actual results could differ materially from any anticipated future results, performance, or achievements. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. Please also see our most recent SEC filings for more information about risk factors that could affect our performance. In addition, during the call, we may refer to several adjusted or non-GAAP financial measures, which may include adjusted gross margin, adjusted EBITDA, adjusted net income from continuing operations, and adjusted earnings per share from continuing operations, which are used in addition to the results presented in accordance with GAAP financial measures. We believe that non-GAAP measures provide us an additional way of viewing aspects of our operations and performance.

Matt HallExecutive Director of Corporate Development and Investor Relations

When considered with GAAP financial measures and the reconciliation of GAAP measures, they provide an even more complete understanding of our business. A reconciliation of these adjusted non-GAAP financial results to the most comparable GAAP measurements are available at the end of the presentation slide deck and our second quarter 2026 press release. With that context, I'll turn the call over to our President and CEO, Steve Griffin, to walk through our performance and discuss our priorities moving forward.

Steve GriffinPresident and CEO

Steve? Thanks, Matt. Good morning, everyone, and thank you for joining us.

Steve GriffinPresident and CEO

The second quarter marked great progress in our efforts to build a stronger, more profitable Anika. We delivered commercial channel revenue growth, significant gross margin expansion, our highest adjusted EBITDA since 2020, and improved profitability while continuing to invest in our growth initiatives. These results reflect execution against the three strategic priorities I highlighted in my first earnings call in February: accelerating sustainable revenue growth, driving operational excellence across the organization, and advancing our hyaluronic acid-based innovation pipeline. Our first priority remains accelerating sustainable revenue growth, and the second quarter results reflect progress in that direction. In the second quarter, commercial channel revenue increased 17% to a record level. This was driven by focused execution and broad growth in our international OA Pain Management and Regenerative Solutions businesses.

Steve GriffinPresident and CEO

The momentum was evident in our international commercial business, where focused execution and portfolio alignment continued to deliver results. Cingal grew 32% and Monovisc grew 24% year-over-year, together contributing approximately $2 million of incremental profitable revenue. The growth we've seen through the first half of the year, with Cingal growing 23% and Monovisc growing 19%, has contributed more than $3 million of incremental revenue. These results underscore the durability and growing scale of our international OA Pain Management franchise. We believe this sustained growth also reflects the benefits of the increased focus and alignment across our international business following the portfolio actions completed over the last 18 months. During the quarter, we hosted our international distributor meeting with more than 35 of our international distributors represented, providing an opportunity to align around growth priorities, share best practices, and strengthen commercial execution.

Steve GriffinPresident and CEO

As our organization and distribution partners increasingly concentrate their attention on our core HA portfolio, we are seeing improved engagement, greater market focus, and stronger execution, which we believe is contributing to the growth trends we are seeing today. Within Regenerative Solutions, Integrity remains a growth driver. Global surgeries and units sold increased both sequentially and year-over-year, with year-to-date sales up approximately 39% and revenue just under $2 million for the second consecutive quarter. Growth was driven by expanding international demand and continued adoption of the larger sizes introduced late last year, reflecting increased surgeon confidence and broader utilization of the platform across a variety of anatomies and tendon applications. We remain encouraged by the progress of Integrity. The recently launched larger sizes have exceeded our initial expectations, supporting our view that the platform can address a broader range of tendon repair procedures and patient anatomies.

Steve GriffinPresident and CEO

We also continue to advance our post-market clinical follow-up study, with enrollment expected to be completed in the coming quarters, further strengthening the clinical evidence supporting the technology and providing the data needed to file in the EU. Internationally, momentum remains positive, with stocking orders outside the U.S. increasing more than 50% in the second quarter, and June representing the strongest month to date. As product availability expands and surgeon experience grows, we believe Integrity is positioned to support continued adoption across both U.S. and international markets. The strength of our HYAFF-driven regenerative business extends beyond Integrity. Hyalofast performed well during the quarter outside the U.S., contributing to double-digit growth in international regenerative solutions revenue. Its sustained adoption and expanding use across geographies highlight the strength and depth of this regenerative hyaluronic acid-based technology. Together, these drivers continue to enhance the franchise's reach and support sustainable long-term growth.

Steve GriffinPresident and CEO

The OEM channel grew 14% year-over-year, driven primarily by favorable order timing across both of our U.S. OA Pain Management products sold through our partnership with J&J DePuy Synthes. Within the portfolio, performance was led by Monovisc unit volumes that exceeded projections for the quarter. Supported by favorable U.S. end market sales, Monovisc more than offset lower than expected Orthovisc revenue. While we believe a portion of the quarter's performance benefited from order timing, underlying demand trends remain encouraging. Given our performance through the first half of the year, we're raising our full year OEM revenue guidance, expecting low double-digit revenue growth. We continue to anticipate quarterly revenue variability due to customer ordering patterns. The current DePuy Synthes team has driven improved demand and enhanced commercial execution. Their focus on physician outreach, customer support, and franchise development has contributed meaningfully to the momentum we are seeing today.

Steve GriffinPresident and CEO

We look forward to continuing to build on that momentum together in the years ahead. While commercial channel execution and our J&J partnership remain important growth drivers, we also continue to focus on opportunities to expand and optimize revenue across our broader OEM product portfolio. We have several longstanding OEM relationships and legacy programs that generate attractive revenue and cash flow, and we continue to evaluate ways to enhance both growth and profitability. While these programs may be smaller individually than our primary growth drivers, collectively, they represent an important contributor to shareholder value and are an area where disciplined execution can drive incremental returns. Our second priority, strengthening operational discipline and execution, has been an increased area of focus and contributed to second quarter financial performance and profitability. Gross margin improved to 65% in the second quarter, representing one of the highest levels we have delivered in recent years.

Steve GriffinPresident and CEO

This performance reflects progress across manufacturing productivity, operational efficiency, product mix, and disciplined execution throughout the organization. Many of the operational improvements contributing to these results are structural. During the first half of the year, we completed several projects to address manufacturing constraints. On our Monovisc and Cingal manufacturing line, we completed a capacity expansion project that effectively doubled throughput at a production step that had previously constrained manufacturing output. We also successfully completed a planned upgrade of our Orthovisc and non-orthopedic manufacturing line, resulting in meaningful improvements in yield, throughput, and production efficiency. These investments strengthen our ability to support future growth while further improving the efficiency and cost structure of our manufacturing operations. Through the first half of the year, we've increased our focus on improving how we can run our core business, and those efforts contributed to our strongest quarterly profitability performance since 2020.

Steve GriffinPresident and CEO

We view current performance as evidence that we are building a more efficient, higher return business, and our teams believe we are in early innings of improving returns. Our focus remains on applying lean principles across the organization, eliminating waste, simplifying processes, and improving productivity. Here in Bedford, we're optimizing our manufacturing operations to increase throughput and maximize facility utilization. We have added targeted headcount to support higher production levels while still increasing gross margin, enabled by process improvements, waste reduction, and a greater focus on value-added activities. In addition, we continue to make capital investments to enhance manufacturing capabilities, increase efficiency, and support future volume growth. Our manufacturing capabilities are becoming an increasingly important competitive advantage, and we believe they can create additional value over time.

Steve GriffinPresident and CEO

While we're encouraged by the early progress made to date, we believe opportunities remain to increase throughput through our facility, improve productivity, and deliver higher profitability. Turning to our third priority, advancing our HA-based innovation pipeline, we continue to make progress across our development programs while building capabilities we believe will strengthen the long-term value of our innovation platform. Our strategy remains focused on leveraging our deep expertise in hyaluronic acid and HYAFF technologies to address unmet needs across OA pain management and regenerative solutions. Starting with Hyalofast, we remain actively engaged with the FDA as the PMA review process continues. We are working through the agency's deficiency letter and expect to complete our response in the coming weeks. Based on our recent engagements, the co-primary endpoints of our clinical study are the most important components of the review and could impact the timeline for ultimate product approval.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day